MedTrace Logo

Atazanavir Twice Daily

NCT00357721 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2011-04-06

No results posted yet for this study

Summary

The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir administered twice-daily relative to historical data from atazanavir/ritonavir 300/100 mg, given once daily.

Conditions

  • HIV Infections
  • Protease Inhibitor

Interventions

DRUG

Atazanavir Sulphate

Capsules, Oral, 200 mg, twice daily, 7 days.

DRUG

Atazanavir Sulphate

Capsules, Oral, 300 mg, twice daily, 8 days.

DRUG

Atazanavir Sulphate

Capsules, Oral, 400 mg, twice daily, 9 days.

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2006-09-30
Completion
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00357721 on ClinicalTrials.gov